EU regulators in April gave the green light to Europe's first "biosimilar" drug, the human growth hormone Omnitrope produced by Novartis subsidiary Sandoz. The drug is a generic for Pfizer's Genotropin and is expected to hit European markets shortly. Around the same time that Sandoz got its EU approval, a US federal judge ordered the Food & Drug Administration to rule on Sandoz's new drug application for Omnitrope, which the company had submitted in 2003.

A new US process for regulating the marketing of biogenerics isn't expected until at least 2007. Though, the European decision might put pressure on the FDA to formulate a policy on the marketing of biosimilars, says Suzette Kox, senior director of scientific affairs at the European Generic Medicines Association.

European health authorities hope biosimilars will offer cost savings for healthcare expenditures. But the ability of companies to turn a profit from small-selling biogenerics is going...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?